TRIB2 and central nervous system cancer: The ROC analysis confirmed that the sensitivity and specificity of TRIB2/MAP3K1 expression were statistically significant, indicating that TRIB2/MAP3K1 expression should be investigated for evaluating the prognosis and therapeutic efficacy in patients with glioma.